In the evolving pharmaceutical landscape of 2026, companies face unprecedented financial pressures on multiple fronts, including rising costs and shrinking opportunities for revenue generation. The Inflation Reduction Act (IRA), now in its fourth year, continues to compress peak sales windows for top-selling drugs through price negotiations. At the same time, tariff threats led to pricing and investment commitments with the Trump Administration that put further pressure on the bottom line. Meanwhile, AI improvements have enabled competitors to rapidly challenge market leaders.

Against this backdrop, stakeholders globally have continued to raise evidence requirements to approve / use new products, especially at premiums to the current standard of care. These financial pressures have simultaneously increased costs and shortened the timeframe in which manufacturers can recoup R&D investments.